Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
SOPHARMA AD (the “Company”) hereby informs that from 16 May 2013 up to and including 22 May 2013 the Company bought 48520 own shares representing 0.037% of the share capital of the Company, to the total value of BGN 139248.98 on the Bulgarian Stock Exchange. The average price per share was BGN 2.87.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 4176521, representing 3.16% of the share capital of the Company.
Sopharma AD (the “Company”) notifies that for April 2013 Sopharma AD realized same level of sales revenues compared to the same period of 2012, including 3% increase of domestic sales and 1% decrease of export sales.
During the past four months Sopharma AD recorded a decrease of sales revenues of 3%, including 4% increase of domestic sales and 6% decrease of export sales compared to 2012.
SOPHARMA AD (the “Company”) hereby informs that from 25 April 2013 up to and including 8 May 2013 the Company bought 108089 own shares representing 0.082% of the share capital of the Company, to the total value of BGN 281132.57 on the Bulgarian Stock Exchange.
The average price per share was BGN 2.60.The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 4113757, representing 3.12% of the share capital of the Company.
Pursuant to art.100k, par.1 of POSA we hereby notify, that the Board of Directors of Sopharma AD authorized the Executive Director to begin negotiations for the sale of all shares representing 85% of the capital of the subsidiary Extab Corporation, owned by Sopharma AD. The negotiations will be conducted as part of the strategy for development of the original products of Sopharma AD on new markets, on which the Company does not possess the necessary resources for such actions in the near future.
SOPHARMA AD (the “Company”) hereby informs that from 9 May 2013 up to and including 15 May 2013 the Company bought 14244 own shares representing 0.01% of the share capital of the Company, to the total value of BGN 38501.05 on the Bulgarian Stock Exchange. The average price per share was BGN 2.70.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 4128001, representing 3.13% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 23 May 2013 up to and including 29 May 2013 the Company bought 24,881 own shares representing 0.019% of the share capital of the Company, to the total value of BGN 72,023.21 on the Bulgarian Stock Exchange. The average price per share was BGN 2.93.
The shares have been bought on the basis of decision No. 7 of the General Meeting from 23 June 2010.
The total number of treasury shares after these transactions is 4,201,402, representing 3.18% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 21 March 2013 up to and including 27 March 2013 the Company bought 13480 own shares representing 0.010% of the share capital of the Company, to the total value of BGN 31354.20 on the Bulgarian Stock Exchange. The average price per share was BGN 2.32.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3666347, representing 2.777% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 14 March 2013 up to and including 20 March 2013 the Company bought 15688 own shares representing 0.012% of the share capital of the Company, to the total value of BGN 3578,38 on the Bulgarian Stock Exchange. The average price per share was BGN 2.28.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3652867, representing 2.767% of the share capital of the Company.
Sopharma AD announces that the Company bought 770 ordinary registered shares with voting rights, representing 0.0455 of the share of the capital of Momina krepost AD. After this transaction the share of Sopharma AD in the capital of Momina krepost AD increased above 50% to 50.01%.
Sopharma will undertake the actions envisaged by the Law for public offering of securities art. 149 in relation to the fact that it now has exceeded the threshold of 50% in the capital of Momina krepost AD.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 7 March 2013 up to and including 13 March 2013 the Company bought 16080 own shares representing 0.012% of the share capital of the Company, to the total value of BGN 36047.53 on the Bulgarian Stock Exchange. The average price per share was BGN 2.24.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3637179, representing 2.755% of the share capital of the Company.